Howard Stern TRT Clinical Interpretation: What His Testosterone Therapy Tells Us

What Howard Stern Has Said About TRT

Howard Stern has discussed his testosterone use on "The Howard Stern Show" across multiple episodes, confirming that he takes testosterone under medical supervision. He has referenced feeling better physically and mentally since starting therapy. These statements are primary, sourced from his own broadcasts, not tabloid speculation.

Public Statements vs. Clinical Reality

Stern's openness matters in a medical context. Many men over 60 experience symptoms of low testosterone (fatigue, reduced libido, loss of muscle mass, cognitive fog) but never seek evaluation. The Endocrine Society's 2018 clinical practice guideline recommends testing morning total testosterone in men with consistent symptoms [1]. Stern's willingness to discuss his treatment may reduce stigma around a condition that affects an estimated 20-40% of men over age 60, depending on the diagnostic threshold used [2].

What We Can Infer (Labeled as Inference)

Stern has not disclosed his specific testosterone formulation, dose, or lab values publicly. Based on standard-of-care protocols for men in his age range, his regimen likely involves one of the following: testosterone cypionate injections (100-200 mg every 1-2 weeks), a transdermal gel (such as AndroGel at 50-100 mg daily), or testosterone pellets implanted subcutaneously every 3-6 months. This is inference based on prescribing norms, not confirmed reporting.

The Clinical Case for TRT in Men Over 65

Testosterone production peaks in a man's late 20s and declines at approximately 1-2% per year after age 30. By age 70, many men have total testosterone levels well below the 300 ng/dL threshold that the American Urological Association (AUA) uses to define testosterone deficiency [3]. Symptoms are nonspecific. They overlap with aging itself.

The Testosterone Trials (TTrials)

The most definitive evidence for TRT in older men comes from the Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with testosterone levels below 275 ng/dL [4]. Over 12 months, men receiving testosterone gel showed statistically significant improvements in sexual desire (measured by the Psychosexual Daily Questionnaire), erectile function, walking distance (measured by the 6-minute walk test), and mood (measured by the PHQ-9 depression scale).

The effect sizes were moderate. Sexual function improved the most. Physical function showed a smaller but real benefit. Bone mineral density increased at the spine and hip, a finding that has particular relevance for men in their 70s facing osteoporosis risk [5].

Who Qualifies for Treatment

The Endocrine Society guideline stipulates that TRT should be reserved for men with both symptoms and two morning total testosterone values below 300 ng/dL [1]. The AUA sets a similar threshold [3]. Testing should occur between 7:00 and 10:00 AM when testosterone is at its circadian peak. Free testosterone and sex hormone-binding globulin (SHBG) measurements are recommended when total testosterone falls in the borderline range (200-400 ng/dL), especially in older or obese men where SHBG elevation can mask true androgen status.

Cardiovascular Safety: The TRAVERSE Trial

The single biggest concern with TRT has been cardiovascular risk. For years, clinicians hesitated to prescribe testosterone to older men because of conflicting observational data. The TRAVERSE trial resolved much of that uncertainty.

Study Design and Results

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-term Vascular Events and Efficacy Response in Hypogonadal Men) enrolled 5,246 men aged 45-80 with hypogonadism and preexisting cardiovascular disease or high cardiovascular risk [6]. Men were randomized to 1.62% testosterone gel or placebo and followed for a mean of 33 months.

The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke (MACE). The hazard ratio was 0.96 (95% CI, 0.78-1.17), confirming non-inferiority. TRT did not increase heart attack or stroke risk compared to placebo.

Nuances Worth Noting

TRAVERSE did find a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group, though these were secondary endpoints and the absolute differences were small [6]. For a man like Stern in his early 70s, this means that cardiovascular safety is reassuring at a population level, but individual monitoring (regular ECG, kidney function, hematocrit) remains necessary.

The FDA updated its labeling for testosterone products in 2024 based on TRAVERSE data, removing the prior boxed warning language about cardiovascular events and instead noting the non-inferiority finding [7].

Expected Benefits at Stern's Age

A man starting or continuing TRT in his early 70s can reasonably expect several clinical outcomes based on trial data. These are not guaranteed, but they represent population-level findings from randomized controlled trials.

Body Composition

A meta-analysis of 59 randomized controlled trials (N=5,331) published in Clinical Endocrinology found that TRT increased lean body mass by an average of 1.6 kg and decreased fat mass by 2.0 kg over treatment periods ranging from 3 to 36 months [8]. Stern has spoken about maintaining his physique, and these data support the plausibility of body composition changes from TRT alone, even without dramatic exercise regimen modifications.

Sexual Function

The TTrials sexual function trial showed that testosterone raised the percentage of men reporting at least a minimally clinically important improvement in sexual desire from 19.8% (placebo) to 46.0% (testosterone) [4]. Erectile function improved but to a lesser degree. For men over 65, TRT is not a substitute for PDE5 inhibitors in cases of established erectile dysfunction, but it can restore baseline desire.

Bone Density

The TTrials bone substudy found that testosterone increased estimated bone strength at the spine by 7.5% over 12 months, measured by quantitative CT [5]. Given that men in their 70s face rising fracture risk (the annual hip fracture rate in men aged 70-79 is approximately 3-4 per 1,000 [9]), this is a clinically meaningful finding.

Cognitive Effects

The TTrials cognitive function trial did not show a significant improvement in cognitive function with testosterone treatment over 12 months [10]. This is a common area of patient expectation that outpaces the evidence. Stern has mentioned mental clarity, but the placebo-controlled data do not support testosterone as a cognitive enhancer in older men.

Monitoring Requirements for Long-Term TRT

Any man on TRT, regardless of celebrity status, requires structured monitoring. The Endocrine Society and AUA guidelines align on the following schedule [1][3].

Baseline Labs Before Starting

Before initiating TRT, clinicians should obtain two morning total testosterone levels, a complete blood count (CBC) with hematocrit, a lipid panel, a hepatic function panel, a PSA level, and a digital rectal exam. Baseline bone density via DEXA should be considered in men over 65 or those with risk factors for osteoporosis.

Ongoing Surveillance

After starting TRT, guidelines recommend checking testosterone levels and hematocrit at 3 months, 6 months, and then every 6-12 months thereafter. The critical safety metric is hematocrit. Testosterone stimulates erythropoiesis, and hematocrit values above 54% require dose reduction or temporary cessation due to thromboembolic risk [1].

PSA should be measured at 3-6 months and then annually. A PSA rise of more than 1.4 ng/mL within 12 months or an absolute value above 4.0 ng/mL warrants urological referral [3]. The relationship between TRT and prostate cancer has been extensively studied. The current evidence, including a large retrospective cohort study of 147,593 men published in JAMA Network Open, does not support an increased prostate cancer risk with TRT [11].

When to Stop

TRT should be discontinued if the patient develops erythrocytosis that does not resolve with dose adjustment, a new prostate cancer diagnosis, severe lower urinary tract symptoms (IPSS score above 19), confirmed hematocrit persistently above 54%, or an adverse cardiovascular event where the risk-benefit calculation shifts.

How Stern's Age Affects the Risk-Benefit Calculus

Being in his early 70s places Stern in a specific clinical category. The TTrials enrolled men 65 and older, so the evidence base directly applies to him. Younger men (under 50) on TRT face different considerations, including fertility suppression. For men over 65, the primary concerns shift to hematologic monitoring, cardiovascular surveillance, and bone health.

Fertility Is Not a Factor

For younger men, TRT suppresses spermatogenesis through negative feedback on the hypothalamic-pituitary-gonadal axis. Exogenous testosterone reduces intratesticular testosterone concentrations by 75-90%, making TRT an effective (though not approved) male contraceptive [12]. For a man in his 70s, this is rarely a clinical concern. If fertility preservation were desired, alternatives like clomiphene citrate or human chorionic gonadotropin (hCG) would be used instead of exogenous testosterone.

Polypharmacy Considerations

Men in their 70s commonly take multiple medications. Testosterone has relatively few drug-drug interactions, but it can potentiate the effect of anticoagulants (increasing INR in men on warfarin) and may affect glycemic control in men on insulin or oral hypoglycemics [1]. A full medication reconciliation is essential before starting TRT in this age group.

What Stern's Case Illustrates About TRT Access

Stern's access to high-quality medical supervision is not typical. He can afford concierge-level endocrinology, frequent lab draws, and personalized dosing adjustments. Most men on TRT in the United States receive prescriptions from primary care physicians who may not follow the monitoring protocols outlined in specialty guidelines.

A 2020 cross-sectional analysis of prescribing patterns published in JAMA Internal Medicine found that 28.6% of men who received a new testosterone prescription had not undergone baseline testosterone testing [13]. Among those who did have testing, 42.5% had levels above 300 ng/dL, meaning they did not meet the standard diagnostic threshold for testosterone deficiency.

This prescribing gap creates risk. TRT in eugonadal men (those with normal testosterone) carries the same side effect profile (erythrocytosis, potential cardiovascular events, testicular atrophy) without the same evidence-based benefits.

The Telehealth Factor

The expansion of telehealth TRT clinics has increased access but also raised concerns about screening quality. The AUA's 2018 position statement emphasizes that testosterone prescribing should follow established diagnostic criteria regardless of the care delivery model [3]. For men considering TRT after hearing about Stern's experience, the clinical message is clear: get two morning testosterone levels drawn, have a full symptom evaluation, and ensure ongoing monitoring before starting treatment.

The Broader TRT Trend in Men Over 60

Testosterone prescriptions in the United States increased by approximately 300% between 2001 and 2013 [14]. After a brief decline following early cardiovascular safety concerns, prescribing has risen again, driven partly by direct-to-consumer marketing and telehealth platforms. Among men aged 60-79, prescription rates remain highest in those with diagnosed hypogonadism, but off-label use for "anti-aging" purposes continues.

The clinical evidence supports TRT for symptomatic testosterone deficiency. It does not support its use as a general anti-aging therapy in men with normal testosterone levels. The distinction matters. Stern's public statements align with appropriate use: he has described symptoms consistent with testosterone deficiency and has pursued treatment under medical supervision.

Men over 60 considering TRT should discuss their symptoms with a clinician, obtain proper diagnostic testing, and commit to ongoing monitoring. The starting dose for most formulations should be the lowest effective amount, with titration based on symptom response and serum testosterone targets of 450-600 ng/dL [1].